February 10, 2026 01:00 ET  | Source: Royal Philips Amsterdam, February 10, 2026 Full year and Q4 highlights Capital Markets Day Roy Jakobs, CEO of Royal Philips:“In 2025, we delivered on our commitments as we scaled better care for more people. We strengthened our company while navigating a dynamic macro-environment. We ended the year with strong order […]

February 09, 2026 04:00 ET  | Source: Open Health New York and London, Feb. 09, 2026 (GLOBE NEWSWIRE) — OPEN Health today announced senior leadership appointments that reinforce the company’s commitment to disciplined growth, enterprise alignment, and the company’s purpose of strengthening the decisions that shape care. As healthcare grows more complex, life-sciences organizations face

February 04, 2026 01:30 ET  | Source: Curium BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) — Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies’ registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic castration-resistant prostate cancer (mCRPC). 177Lu-PSMA-I&T is a radiotherapeutic agent